Investment, Funding & Disinvestments

The agreement extends the biotechnology company’s partnership with the Biomedical Advanced Research and Development Authority (BARDA), established in 2020.

Once expanded, the facility could have a total reactor volume exceeding 400 m³, increasing the company’s capacity to develop and manufacture active pharmaceutical ingredients (APIs).

Kaigene is developing the antibody for long-acting subcutaneous administration to maintain target inhibition over extended intervals and reduce treatment frequency.

Gilead is exploring HCXT-2001 as a potential oral treatment that could complement its existing inflammation portfolio, which includes programmes targeting IBD, type 2 inflammatory diseases, lupus and B cell-mediated autoimmune conditions.

CMR Surgical will continue to develop its products and manage commercialisation in markets outside the US.

Xodus Medical develops surgical products used in patient positioning, sterile processing and operating rooms, giving Steris a broader range of consumables for hospital customers.

Under the agreement, Labcorp will pay US$722 million in cash upfront for BioReference’s clinical and women’s health testing businesses, urology services, corrections testing operations and related assets.

The programme includes a Phase I trial in healthy volunteers, followed by a Phase Ib trial in hospitalised patients with acute liver injury, acute liver failure or acute-on-chronic liver failure.

The acquisition gives Merck access to divesiran, an investigational small interfering RNA (siRNA) therapy for polycythemia vera (PV), a rare blood cancer characterised by excessive red blood cell production.

Developed through a joint venture between M42 and Bahraini partner HealthVision, Mubadala Health Bahrain will bring multiple medical specialties and diagnostic services under one roof.